Effect of lipoprotein(a) levels on long-term outcome in octogenarians with coronary artery disease after drug-eluting stent implantation

Rev Cardiovasc Med. 2022 Mar 1;23(3):79. doi: 10.31083/j.rcm2303079.

Abstract

Background: High levels of lipoprotein(a) [Lp(a)] are linked to adverse cardiovascular events. The significance of Lp(a) for the survival of octogenarians with coronary artery disease (CAD) after drug-eluting stent (DES) insertion is, however, not known. The purpose of the study is to investigated the connection between Lp(a) and outcome in octogenarians with CAD after DES implantation.

Methods: We retrospectively enrolled a total of 506 consecutive octogenarians with CAD and DES implantation in our institution between January 2015 to August 2018. Two patient groups were established: a low group with plasma Lp(a) lower than 50 mg/dL (n = 408) and a high group with values above 50 mg/dL (n = 98).

Results: After following up for a median of 31.53 ± 8.22 months, Kaplan-Meier curves indicated that poorer outcome censored for major cardiovascular events (MACE), myocardial infarction (MI), and target vessel revascularization (TVR) in the high group relative to the low group (log-rank test p = 0.001, p = 0.008, and p < 0.001, respectively). High Lp(a) independently predicted MACE (hazard ratio (HR) 1.90; 95% confidence interval (CI) 1.28-2.84; p = 0.002), MI (HR 2.74; 95% CI 1.23-6.11; p = 0.014), and TVR (HR 3.65; 95% CI 1.99-6.69; p < 0.001) after covariate adjustment.

Conclusions: High Lp(a) was also significantly related to poor long-term outcome in octogenarians with CAD after DES implantation.

Keywords: Coronary artery disease; Drug-eluting stent; Lipoprotein(a); Octogenarian.

MeSH terms

  • Aged, 80 and over
  • Coronary Artery Disease* / diagnostic imaging
  • Coronary Artery Disease* / etiology
  • Coronary Artery Disease* / therapy
  • Drug-Eluting Stents* / adverse effects
  • Humans
  • Lipoprotein(a)
  • Myocardial Infarction*
  • Octogenarians
  • Percutaneous Coronary Intervention* / adverse effects
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Lipoprotein(a)